Huhn, Gregory D <br/><br/>
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.  [electronic resource] 

 -  AIDS research and therapy  08 2019 
 - 23 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1742-6405 
<br/><br/><label>Standard No.: </label>10.1186/s12981-019-0235-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adult<br/>Aged<br/>Alanine<br/>Anti-HIV Agents--therapeutic use<br/>Antiretroviral Therapy, Highly Active<br/>Cobicistat--therapeutic use<br/>Darunavir--therapeutic use<br/>Drug Combinations<br/>Drug Substitution<br/>Emtricitabine--therapeutic use<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Protease Inhibitors--therapeutic use<br/>Sustained Virologic Response<br/>Tablets<br/>Tenofovir--therapeutic use<br/>Viral Load--drug effects<br/>Young Adult